Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
0 hedge funds and large institutions have $0 invested in Aerie Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 153 closing their positions.
100% less funds holding
Funds holding: 156 → 0 (-156)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $711M → $0 (-$711M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 153
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$73.5M |
| 2 |
BlackRock
New York
|
-$53.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$36.9M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$36.4M |
| 5 |
WIC
Water Island Capital
New York
|
-$31.5M |
AERI Hedge Fund Activity: Q4 2022 in Review
0 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2022, worth a combined $0 — down 100% from $711M a quarter earlier.
Sellers outnumbered buyers: 153 funds closed out of AERI and 0 opened new positions — a net loss of 153 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Deerfield Management, exiting entirely with an estimated $73.5M sold.
- 0 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2022, down from 156 in Q3 2022.
- Funds reported $0 of Aerie Pharmaceuticals stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Aerie Pharmaceuticals positions in Q4 2022 and 153 closed out, a net change of -153 holders.
- The largest Aerie Pharmaceuticals seller in Q4 2022 was Deerfield Management, an estimated $73.5M sold.
Based on aggregated 13F filings for Q4 2022.